Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Cash flows from operating activities:
Net income (loss)	$ 12,500	$ (15,675)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Change in fair value of warrant liability	(10,807)	1,316
Depreciation and amortization	4,964	7,010
Amortization of deferred financing costs	1,987	1,516
Accretion of debt discount	2,657	2,451
Gain on sale of assets	(1,428)	(132)
Stock compensation expense	2,698	3,839
Deferred income tax benefit	(160)	(1,166)
Reduction in (excess) tax benefit related to share-based awards	(229)	1,685
Loss on extinguishment of debt	3,225	995
Change in current assets and liabilities:
Accounts receivable	(11,048)	(5,364)
Inventories, net	(8,429)	420
Accrued liabilities	(1,152)	2,277
Interest payable	(30)	(691)
Accounts payable	1,254	222
Other current assets	(1,806)	(520)
Income tax receivable, net	2,414	(3,103)
Restricted cash		10
Net cash used in operating activities	(3,390)	(4,910)
Cash flows from investing activities:
Capital expenditures	(3,657)	(2,183)
Proceeds from sale of assets	2,279	1,343
Purchase of patents and other intangibles	(220)	2
Net cash used in investing activities	(1,598)	(838)
Cash flows from financing activities:
Proceeds from sale of common stock	29,438
Proceeds from exercise of warrants	4,581	69
Debt issuance costs	(1,000)	(1,742)
Repayments of indebtedness	(32,871)	(32,022)
(Reduction in) excess tax benefit related to share-based awards	229	(1,685)
Purchase of treasury stock	(199)	(86)
Proceeds from exercise of stock options	109	3
Proceeds from borrowings		40,000
Net cash provided by financing activities	287	4,537
Effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency	(25)	(9)
Net decrease in cash and cash equivalents	(4,726)	(1,220)
Cash and cash equivalents at the beginning of period	19,863	6,485
Cash and cash equivalents at the end of period	$ 15,137	$ 5,265